title: [A new clinical disease entity. Tuberculosis in users of TNF-alpha inhibitors].
authors.affiliation: Institut für Krankenhaushygiene, Klinikum Stuttgart, Kriegsbergstraße 60, Stuttgart. m.trautmann@klinikum-stuttgart.de
authors.forename: Matthias
authors.initials: M
authors.lastname: Trautmann
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D005858:Germany / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012306:Risk; D014376:Tuberculosis / Q000453:epidemiology* / Q000382:microbiology / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept